Evolus to Participate in Two Upcoming Investor Conferences

IRVINE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, announced today that members of management will be participating in two upcoming investor conferences.

An audio webcast of the Company’s presentation at the Stifel 2018 Healthcare Conference will be available on the investor relations section of Evolus’ website at investors.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate DWP-450, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.

Evolus Contacts:

Investors Ashwin Agarwal, Evolus Tel: +1-949-284-4559 Email: [email protected] 

Brian Johnston, The Ruth Group Tel: +1 646-536-7028 Email: [email protected] 

General Media Kirsten Thomas, The Ruth Group Tel: +1-508-280-6592 Email: [email protected]

Trade Media Dani Shaffer, Alison Brod Marketing + Communications Tel: +1-212-230-1800 Email: [email protected] 

You May Also Be Interested In

• Ivie Realty Announces Expanded Investor Services Through BrokenBowInvestors.com to Support Oklahoma's Growing Short Term Rental Market
• The Tax Refinery Announces Year Round Tax Advisory Model to Help Business Owners Shift From Reactive Filing to Strategic Planning
• Salus Scientific Welcomes Landmark Multi-Society Consensus Statement Advancing the Future of Occupational Radiation Safety